J&J starts human study of COVID-19 vaccine after promising monkey data

J&J starts human study of COVID-19 vaccine after promising monkey data

An expert committee studying Serum Institute of India's request to start late-stage human trials in India for a Covid-19 vaccine candidate developed by the University of Oxford has deferred its decision on the matter until the Pune-headquartered firm revises its proposal.

The final price for Moderna's Covid-19 vaccine has yet to be determined, said a person familiar with the discussions. Volunteers receive either a vaccine or a placebo injected at two points 28 days apart.

"This study shows that even just a single immunization with the Ad26 vaccine leads to neutralizing antibody responses and robust protection of monkeys against COVID-19", said Dr. Dan Barouch, a vaccine researcher at Beth Israel Deaconness who led the research in collaboration with J&J.

The Financial Times (FT) has quoted unnamed sources as saying that the United States biotechnology company Moderna plans to price its COVID-19 vaccine at about $50-$60 per course.

What Happened: "All the countries that are developed right now will not receive a lower price for the same volume commitment than the U.S.", Bourla said, as earlier reported by Reuters.

Rep. John Lewis’ Funeral, Burial Set for Thursday
House of Representatives for Georgia's 5th district (D). Ever since 1987, Lewis has been a member of the U.S. Three former presidents - Barack Obama , George W.

In other words: the federal government has agreed to pay Pfizer to produce enough vaccine to give one dose to about a third of the US population - even though it's not yet approved and the final phase of testing hasn't even begun. The company's treatment uses a common cold virus that causes the body to mount an immune defense. AstraZeneca, for example, has signed an agreement with the Netherlands, Germany, France, and Italy for a vaccine that would cost between $3 and $4 per dose.

The World Health Organization has said multiple vaccine approaches are necessary for COVID-19, noting that the usual success rate for vaccine development is about 10%. The Phase 3 trial of this vaccine will also be conducted in several other countries including India.

Six vaccine candidates are now in the late phases of human trials. It has also recommended that the clinical trial sites being proposed for the study be "distributed across pan-India". "We do not know how well these vaccines are going to work until we finish our clinical trials process", he said.

The approval for the Recombinant Novel Coronavirus Vaccine (Ad5-nCoV) was granted on June 25, for one year.

Six weeks later, all of the animals were exposed to the SARS-CoV-2 virus.

Related Articles